PSIL holdings
All 32 positions of AdvisorShares Psychedelics ETF.
Positions
32
Top 10 weight
69.2%
Effective holdings
14.1
1 / sum of squared weights
In stocks
95.9%
In bonds
0.0%
Outside the US
45.3%
Asset mix
Sectors
91% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | DFTXDefinium Therapeutics, Inc. Common Shares | Equity | 12.85% | $5.7M | 121,381 | CA |
| 2 | CMPSCOMPASS Pathways Plc American Depository Shares | Equity | 11.45% | $5.1M | 359,647 | GB |
| 3 | ATAIAtaiBeckley Inc. Common Stock | Equity | 10.47% | $4.7M | 882,892 | US |
| 4 | RLMDRelmada Therapeutics, Inc. Common Stock | Equity | 6.84% | $3.0M | 438,901 | US |
| 5 | NRXPNRX Pharmaceuticals, Inc. Common Stock | Equity | 6.07% | $2.7M | 659,018 | US |
| 6 | NBIXNeurocrine Biosciences Inc | Equity | 4.38% | $1.9M | 11,553 | US |
| 7 | HELPHelus Pharma Inc. Common Stock | Equity | 4.35% | $1.9M | 292,711 | CA |
| 8 | GH RESEARCH PLC | Equity | 4.31% | $1.9M | 71,267 | IE |
| 9 | ALKERMES PLC | Equity | 4.30% | $1.9M | 36,438 | IE |
| 10 | ANROAlto Neuroscience Inc. | Equity | 4.20% | $1.9M | 70,748 | US |
| 11 | ABBVABBVIE INC. | Equity | 4.14% | $1.8M | 7,318 | US |
| 12 | BLACKROCK TREASURY TRUST | Cash | 3.97% | $1.8M | 1,763,357 | US |
| 13 | DRUGBright Minds Biosciences Inc. Common Stock | Equity | 3.84% | $1.7M | 24,274 | CA |
| 14 | JNJJohnson & Johnson | Equity | 3.61% | $1.6M | 6,308 | US |
| 15 | DREY INST PREF GOV MM-M | Cash | 3.10% | $1.4M | 1,378,957 | US |
| 16 | SUPNSupernus Pharmaceuticals, Inc. | Equity | 2.89% | $1.3M | 27,618 | US |
| 17 | NEUPNeuphoria Therapeutics Inc. Common Stock | Equity | 2.49% | $1.1M | 252,909 | US |
| 18 | STIMNeuronetics, Inc. Common Stock | Equity | 2.17% | $966K | 742,795 | US |
| 19 | QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | Equity | 1.66% | $737K | 203,564 | CA |
| 20 | OPTHOptimi Health Corp. Common Shares | Equity | 1.18% | $523K | 102,794 | CA |
| 21 | KTTAPasithea Therapeutics Corp. Common Stock | Equity | 1.09% | $483K | 937,550 | US |
| 22 | SILOSilo Pharma, Inc. Common Stock | Equity | 1.06% | $469K | 75,582 | US |
| 23 | PBMPsyence Biomedical Ltd. Common Shares | Equity | 0.84% | $374K | 122,184 | CA |
| 24 | IXHLIncannex Healthcare Limited Common Stock | Equity | 0.52% | $229K | 60,868 | US |
| 25 | NUMIFNUMINUS WELLNESS INC | Equity | 0.47% | $209K | 8,482,082 | CA |
| 26 | IGCIGC Pharma, Inc. | Equity | 0.42% | $185K | 678,480 | US |
| 27 | VTGNVistagen Therapeutics, Inc. Common Stock | Equity | 0.22% | $99K | 438,643 | US |
| 28 | ENVBEnveric Biosciences, Inc. Common Stock | Equity | 0.11% | $49K | 35,417 | US |
| 29 | CMNDClearmind Medicine Inc. Common Shares | Equity | 0.01% | $3K | 1,169 | CA |
| 30 | QUANTUM BIOPHARMA | Equity | 0.00% | $0 | 46,617 | CA |
| 31 | SAGE THERAPEUTICS INC | Equity | 0.00% | $0 | 89,780 | US |
| 32 | UNBUZZD WELLNESS INC | Equity | 0.00% | $0 | 263,236 | CA |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Decrease | DFTXDEFINIUM THERAPEUTICS INC | 8.52% | 12.85% | −14.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | STIMNEURONETICS INC | 4.42% | 2.17% | −22.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | OPTHOPTIMI HEALTH CORP | — | 1.18% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | QNTMQUANTUM BIOPHARMA LTD | 2.59% | 1.66% | +20.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | PBMPSYENCE BIOMEDICAL LTD | — | 0.84% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | DRUGBRIGHT MINDS BIOSCIENCES INC | 4.55% | 3.84% | +23.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | IGCIGC PHARMA INC | — | 0.42% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ANROALTO NEUROSCIENCE INC | 4.55% | 4.20% | +10.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | GH RESEARCH PLC | 4.65% | 4.31% | −31.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ABBVABBVIE INC | 4.47% | 4.14% | +13.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ALKERMES PLC | 4.60% | 4.30% | −11.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | IXHLINCANNEX HEALTHCARE INC | 0.36% | 0.52% | +59.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | KTTAPASITHEA THERAPEUTICS CORP | 1.24% | 1.09% | +78.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ENVBENVERIC BIOSCIENCES INC | 0.16% | 0.11% | +34.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Atai Beckley NV | 12.14% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | ATAIATAIBECKLEY INC | — | 9.92% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | SUPNSupernus Pharmaceuticals, Inc | 7.64% | 4.46% | −42.5% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | STIMNeuronetics Inc | 2.02% | 4.42% | +113.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | RLMDRelmada Therapeutics Inc. | 8.35% | 10.17% | −13.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | Incannex Healthcare Inc | 1.29% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | JNJJohnson & Johnson | 3.42% | 4.56% | +15.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | DFTXDEFINIUM THERAPEUTICS INC | 7.45% | 8.52% | −16.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ABBVAbbVie Inc. | 3.64% | 4.47% | +32.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | QNTMQuantum Biopharma Ltd | 1.96% | 2.59% | +104.8% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | NRXPNRX Pharmaceuticals Inc | 4.81% | 4.42% | +20.0% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | IXHLINCANNEX HEALTHCARE INC | — | 0.36% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | DRUGBright Minds Biosciences Inc | 4.20% | 4.55% | +18.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ANROAlto Neuroscience Inc | 4.25% | 4.55% | −12.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | NBIXNeurocrine Biosciences Inc | 4.53% | 4.66% | +13.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | Alkermes PLC | 4.63% | 4.60% | −19.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.